1. Where do we go from here? Gottfried Hirnschall Director HIV dept, WHO
Monday, 23 July, 10:15-12:15
Hall 11B, RAI Amsterdam

2. In Summary…
Children are still getting infected and still not getting the best drugs in the formulations they need .
We need acceleration and we can’t do business as usual
There is a solid ground to build on – existing platforms and enthusiastic donors in drug optimization
GAP-f depends on strong partnerships with industry
Need for concrete action – joined forces – and accountability

3. WHO’s commitment WHO R&D roadmap launched at WHA
Convene and lead GAP-f - critical partnerships required
GAP-f holds potential for broader pediatric drug needs - contributing to reaching UHC
GAP-f capitalizes on scientific, global health and business experience
GAP-f to contribute to health care equity for all children around the world – leaving no-one behind!

4. Next Steps Develop a business plan – draft end 2018
Assess potential of the GAP-f initiative to other disease areas
Proactively follow up with industry partners on existing plans and commitments
Stay connected and give us your feedback!

5. Toolkit for research and development of paediatric antiretroviral drugs and formulations
In collaboration with experts from the Paediatric Antiretroviral Working Group
Available at

6. AIDS FREE TOOLKIT FOR THE ACCELERATION OF TESTING AND TREATMENT
The AIDS Free Working Group
Is pleased to announce the launch of a new
AIDS FREE TOOLKIT FOR THE ACCELERATION OF TESTING AND TREATMENT
SCALE-UP IN CHILDREN AND ADOLESCENTS LIVING WITH HIV
Available at:

7. Key publications available at www.gap-f.org
Articles in The Lancet HIV and JIAS
Supplements in JAIDS and JIAS